Latest Options News

ARB Corporation Limited has announced a fully franked ordinary dividend of AUD 0.34 per share for the half-year ending December 2024, alongside Dividend Reinvestment and Bonus Security Plans.

Antilles Gold Limited is raising $1 million through a share and option placement to support working capital and development of its Nueva Sabana copper-gold mine in Cuba.

Riversgold Ltd has exercised its option to acquire an 80% interest in the Kalgoorlie Gold Project after surpassing the minimum expenditure threshold, setting the stage for expanded drilling and potential mining lease conversion.

Saturn Metals reports robust assay results from 38 drill holes at Apollo Hill, reinforcing the continuity of its 2.03 million ounce gold resource and highlighting significant growth potential ahead of a planned resource upgrade in late 2025.

SEEK Limited has announced a fully franked ordinary dividend of AUD 0.24 per share for the six months ending December 2024, signalling steady shareholder returns.

Rapid Lithium has successfully placed the full $1 million shortfall from its recent entitlement issue, positioning the company to advance exploration projects in Canada and the USA.

WAM Active Limited has announced a fully franked ordinary dividend of AUD 0.03 per share for the half-year ending December 2024, reinforcing its steady income return strategy.

Ansell Limited has updated its FY25 interim dividend details, confirming a payment of USD 0.222 per share with an AUD equivalent of 0.3486, payable on March 6, 2025.

Maronan Metals has reported outstanding metallurgical test results from its carbonate-hosted silver-lead ore, producing high-grade concentrates with recoveries exceeding 90%, reinforcing the project's economic potential.

BHP Group Limited has announced a fully franked dividend of USD 0.50 per share for the half-year ending December 2024, payable on March 27, 2025, with multiple currency payment options and a Dividend Reinvestment Plan available.

Opthea has completed the final patient visit in its pivotal COAST Phase 3 trial evaluating sozinibercept combined with aflibercept for wet AMD, with topline results expected early Q2 2025.

Brightstar Resources Limited reveals an ambitious growth strategy targeting a significant production ramp-up in 2025, anchored by its Laverton and Menzies hubs and supported by a robust mineral resource base.